V6383
Vinpocetine
≥98%, Ca²⁺-calmodulin-dependent phosphodiesterase I inhibitor, solid
Synonym(s):
(3α,16α)-Eburnamenine-14-carboxylic acid ethyl ester, Eburnamenine-14-carboxylic acid ethyl ester
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C22H26N2O2
CAS Number:
Molecular Weight:
350.45
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
41106305
EC Number:
256-028-0
MDL number:
Product Name
Vinpocetine, ≥98%, solid
Quality Level
assay
≥98%
form
solid
color
white
solubility
DMSO: 5 mg/mL, H2O: insoluble
SMILES string
[H][C@]12N3CCC[C@@]1(CC)C=C(C(=O)OCC)n4c2c(CC3)c5ccccc45
InChI
1S/C22H26N2O2/c1-3-22-11-7-12-23-13-10-16-15-8-5-6-9-17(15)24(19(16)20(22)23)18(14-22)21(25)26-4-2/h5-6,8-9,14,20H,3-4,7,10-13H2,1-2H3/t20-,22+/m1/s1
InChI key
DDNCQMVWWZOMLN-IRLDBZIGSA-N
Gene Information
human ... PDE1A(5136), PDE1B(5153), PDE1C(5137)
Biochem/physiol Actions
Ca2+-calmodulin-dependent phosphodiesterase I (PDE1) inhibitor.
Features and Benefits
This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Phosphodiesterases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Disclaimer
Photosensitive
Still not finding the right product?
Explore all of our products under Vinpocetine
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
Storage Class
11 - Combustible Solids
wgk
WGK 3
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
A A Skoromets et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 113(4), 18-24 (2013-06-07)
Authors studied impairment of cognitive functions in 180 patients, aged 56-74 years, with chronic blood flow deficiency in the vertebrobasilar territory. Along with neurological examination, we used MRI of the brain and the cervical spine, MRI-angiography, ultrasound Doppler method, EEG
Alexei V Muravyov et al.
Clinical hemorheology and microcirculation, 49(1-4), 431-439 (2012-01-05)
This study was designed to evaluate hemorheological changes in patients with cerebrovascular disease (CVD) and peripheral arterial disease (PAD) after 4 weeks of pentoxifylline therapy as well as to study red blood cell microrheological variables after the cell incubation with
Tomasz Sozański et al.
Pharmacological reports : PR, 63(5), 1258-1263 (2011-12-20)
Previous studies proved that food strongly enhanced the bioavailability of vinpocetine. Food may change the pharmacokinetics of a drug by affecting various factors, including gastrointestinal pH. However, the influence of proton pump inhibitor-induced pH alterations on vinpocetine pharmacokinetics is not